{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:42:53Z","timestamp":1784724173204,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jocn-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.jocn.2015.10.008","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T18:43:13Z","timestamp":1447872193000},"page":"75-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-4693","authenticated-orcid":false,"given":"Felix","family":"Benninger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela J.","family":"Glat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Offen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2015.10.008_b0005","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1212\/WNL.30.5.453","article-title":"Epidemiology of amyotrophic lateral sclerosis: 1. A case-control comparison based on ALS deaths","volume":"30","author":"Kurtzke","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2015.10.008_b0010","first-page":"385","article-title":"Incidence of amyotrophic lateral sclerosis in Europe","volume":"81","author":"Logroscino","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2015.10.008_b0015","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1212\/WNL.43.4.751","article-title":"The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials","volume":"43","author":"Pradas","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2015.10.008_b0020","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1212\/01.wnl.0000260965.20021.47","article-title":"Focality of upper and lower motor neuron degeneration at the clinical onset of ALS","volume":"68","author":"Ravits","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2015.10.008_b0025","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1212\/WNL.59.5.773","article-title":"Premorbid weight, body mass, and varsity athletics in ALS","volume":"59","author":"Scarmeas","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2015.10.008_b0030","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrn1971","article-title":"Molecular biology of amyotrophic lateral sclerosis: insights from genetics","volume":"7","author":"Pasinelli","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.jocn.2015.10.008_b0035","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/jnnp.2010.218982","article-title":"Physical fitness, but not muscle strength, is a risk factor for death in amyotrophic lateral sclerosis at an early age","volume":"83","author":"Mattsson","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2015.10.008_b0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.tins.2014.05.006","article-title":"Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies","volume":"37","author":"Vucic","year":"2014","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.jocn.2015.10.008_b0045","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbadis.2014.08.010","article-title":"Sporadic and hereditary amyotrophic lateral sclerosis (ALS)","volume":"1852","author":"Ajroud-Driss","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jocn.2015.10.008_b0050","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrn1870","article-title":"Astrocyte dysfunction in neurological disorders: a molecular perspective","volume":"7","author":"Seifert","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.jocn.2015.10.008_b0055","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/mus.20768","article-title":"Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease?","volume":"35","author":"Neusch","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2015.10.008_b0060","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jnr.490380312","article-title":"Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis","volume":"38","author":"Nagy","year":"1994","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.jocn.2015.10.008_b0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0022-510X(96)00073-1","article-title":"Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis","volume":"139","author":"Schiffer","year":"1996","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2015.10.008_b0070","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.nurt.2010.05.012","article-title":"Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes","volume":"7","author":"Vargas","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jocn.2015.10.008_b0075","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/jnnp.2008.150698","article-title":"Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker","volume":"80","author":"Misu","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2015.10.008_b0080","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ncpneuro0355","article-title":"Mechanisms of disease: astrocytes in neurodegenerative disease","volume":"2","author":"Maragakis","year":"2006","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.jocn.2015.10.008_b0085","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/glia.20836","article-title":"Live imaging of amyotrophic lateral sclerosis pathogenesis: Disease onset is characterized by marked induction of GFAP in Schwann cells","volume":"57","author":"Keller","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.jocn.2015.10.008_b0090","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1586\/14737159.8.4.479","article-title":"Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases","volume":"8","author":"Tumani","year":"2008","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.jocn.2015.10.008_b0095","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s00415-010-5876-x","article-title":"Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases","volume":"258","author":"Jesse","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2015.10.008_b0100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0022-510X(94)90191-0","volume":"124","author":"Brooks","year":"1994","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2015.10.008_b0105","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0022-510X(99)00209-9","article-title":"Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research","volume":"169","author":"Miller","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2015.10.008_b0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/intimm\/dxu099","article-title":"Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective","volume":"27","author":"Malaspina","year":"2015","journal-title":"Int Immunol"},{"key":"10.1016\/j.jocn.2015.10.008_b0115","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.tins.2014.07.008","article-title":"Modeling motor neuron disease: the matter of time","volume":"37","author":"Arbab","year":"2014","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.jocn.2015.10.008_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2014.06.003","article-title":"Intrathecal infusion of BMAA induces selective motor neuron damage and astrogliosis in the ventral horn of the spinal cord","volume":"261","author":"Yin","year":"2014","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jocn.2015.10.008_b0125","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199205283262204","article-title":"Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis","volume":"326","author":"Rothstein","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2015.10.008_b0130","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1073\/pnas.032539299","article-title":"Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS)","volume":"99","author":"Howland","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jocn.2015.10.008_b0135","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/nn.2210","article-title":"Focal transplantation\u2013based astrocyte replacement is neuroprotective in a model of motor neuron disease","volume":"11","author":"Lepore","year":"2008","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jocn.2015.10.008_b0140","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nn1876","article-title":"Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons","volume":"10","author":"Nagai","year":"2007","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jocn.2015.10.008_b0145","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.stem.2008.11.004","article-title":"ALS model glia can mediate toxicity to motor neurons derived from human embryonic stem cells","volume":"3","author":"Hedlund","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jocn.2015.10.008_b0150","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.stem.2008.09.017","article-title":"Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation","volume":"3","author":"Di Giorgio","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jocn.2015.10.008_b0155","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.stem.2008.10.001","article-title":"Non-cell-autonomous effect of human SOD1G37R astrocytes on motor neurons derived from human embryonic stem cells","volume":"3","author":"Marchetto","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jocn.2015.10.008_b0160","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.STR.12.6.879","article-title":"Complications of lumbar puncture followed by anticoagulation","volume":"12","author":"Ruff","year":"1981","journal-title":"Stroke"},{"key":"10.1016\/j.jocn.2015.10.008_b0165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0733-8619(05)70368-6","article-title":"Complications of lumbar puncture","volume":"16","author":"Evans","year":"1998","journal-title":"Neurol Clin"},{"key":"10.1016\/j.jocn.2015.10.008_b0170","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0022-510X(95)00152-R","article-title":"Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit","volume":"133","author":"Rosengren","year":"1995","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2015.10.008_b0210","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/brain\/awf165","article-title":"Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations","volume":"125","author":"Petzold","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2015.10.008_b0215","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0165-0270(94)90011-6","article-title":"A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults","volume":"51","author":"Rosengren","year":"1994","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.jocn.2015.10.008_b0220","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jim.2004.01.015","article-title":"An ELISA for glial fibrillary acidic protein","volume":"287","author":"Petzold","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jocn.2015.10.008_b0195","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2015.10.008_b0200","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jocn.2015.10.008_b0205","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586815005329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586815005329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T12:24:01Z","timestamp":1537187041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586815005329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":40,"alternative-id":["S0967586815005329"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2015.10.008","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2015.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}